OUTSPOKEN ONCOLOGY

Episode 54: Physician Debate on the US Payer System With Rafael Fonseca and Saurabh Jha

05/03/2022

Rafael Fonseca, MD, and Saurabh Jha, MD, debate the benefits and disadvantages of a third-party vs single payer system, whether Medicare has been a successful program for qualifying patients, and the fairness of judging the health care system based on life expectancy.

Dr Fonseca consults for Amgen, BMS, Celgene, Takeda, Bayer, Janssen, AbbVie, Pharmacyclics, Merck, Sanofi, and Kite. He also has stock options in SAB: Adaptive Biotechnologies. Dr Nabhan and Dr Jha have no relevant financial disclosures.

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Videos

Understanding the Impact of Venture Capital and Private Equity in Oncology

11/18/2024

Michael Kolodziej , MD;

Michael Kolodziej, MD, discusses the growing influence of venture capital and private equity in oncology care, highlighting the potential for these trends to reshape costs, partnerships, and innovation in the oncology landscape.

Michael Kolodziej, MD, discusses...

11/18/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

News

Thrombosis and Inflammation Drive Mortality and Cancer Risk in Myeloproliferative Disorders

11/15/2024

Lisa Kuhns , PhD, MD;

Despite the advancements in treatment, thrombosis remains a significant challenge for patients with myeloproliferative neoplasms (MPNs), leading to increased mortality and the development of secondary cancers.

Despite the advancements in...

11/15/2024

Journal of Clinical Pathways

Videos

Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies

11/14/2024

Sawsan Rashdan , MD;

Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.

Dr. Sawsan Rashdan, an associate...

11/14/2024

Journal of Clinical Pathways

News

Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy

11/13/2024

Hannah Musick ;

Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...

Combining immunotherapy with...

11/13/2024

Journal of Clinical Pathways

Episode 54: Physician Debate on the US Payer System With Rafael Fonseca and Saurabh Jha

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products